Looking for research-grade compounds?
PT-141, also known in scientific circles as bremelanotide, is a synthetic cyclic heptapeptide that has garnered significant attention in the realm of biochemical research. As a melanocortin receptor agonist, PT-141 is particularly noted for its interactions with specific receptor subtypes, such as MC1R and MC4R, within laboratory settings. Originally derived from melanotan research programs, PT-141 is strictly utilized for research purposes and is not intended for human or veterinary use. This article delves into the research history, receptor interactions, and laboratory handling considerations of PT-141, providing a comprehensive overview for researchers.
PT-141 emerged from research initiatives that focused on the melanotan peptide family, initially developed to stimulate melanin production and induce tanning without exposure to ultraviolet light. This line of research led to the discovery of various peptides with diverse receptor affinities and potential applications in scientific studies. PT-141 itself was synthesized following observations of specific melanocortin receptor interactions, leading to extensive laboratory investigations aimed at understanding its biochemical properties and receptor-binding dynamics.
The journey from melanotan research to the synthesis of PT-141 underscores the peptide’s importance as a tool for exploring receptor biology and its potential implications. Researchers have concentrated efforts on elucidating the binding characteristics of PT-141, particularly its affinities for the MC1R and MC4R subtypes, which are pivotal in understanding its functional implications within a controlled laboratory environment.
Understanding where PT-141 stands from a regulatory perspective helps researchers contextualize the compound:
FDA approval: Yes. Bremelanotide (PT-141) received FDA approval in 2019 under the brand name Vyleesi, indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) — low sexual desire that causes marked distress and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance. The approved indication specifically does not cover postmenopausal women or men. This makes it one of the few melanocortin-targeting peptides to complete the full regulatory pathway. In media coverage, Vyleesi has sometimes been nicknamed “female Viagra”; however, unlike sildenafil (Viagra), which acts on blood flow, bremelanotide is a melanocortin receptor agonist acting in the brain on pathways involved in sexual desire.
Testing stage: PT-141 completed Phase 1, Phase 2, and Phase 3 clinical trials prior to approval. The Phase 3 program evaluated the compound in controlled clinical settings before the FDA granted marketing authorization.
Research purpose: In laboratory settings, PT-141 is studied as a model melanocortin receptor agonist. Researchers use it to investigate MC1R and MC4R signaling pathways, receptor selectivity, and structure-activity relationships within the melanocortin family. Its approved status also makes it a useful reference compound when comparing investigational melanocortin agonists.
Important note: The research-grade PT-141 supplied for laboratory use is a research chemical and is not the FDA-approved pharmaceutical product. It is strictly for in vitro and laboratory research — not for human or veterinary use.
PT-141’s primary research interest lies in its role as an agonist for melanocortin receptors, specifically MC1R and MC4R. These receptors belong to the G-protein-coupled receptor (GPCR) family, a class involved in numerous physiological processes. Within laboratory settings, PT-141’s ability to selectively bind and activate these receptor subtypes has been a focal point of research, offering insights into receptor-mediated signaling pathways.
The MC1R is predominantly expressed in melanocytes and is primarily associated with pigment production. However, research indicates that this receptor may also be involved in other cellular processes, making it a valuable target for scientific investigation. PT-141’s interaction with MC1R provides researchers with a model for studying receptor activation and the subsequent intracellular signaling cascades. This can help elucidate broader aspects of GPCR function and regulation.
The MC4R receptor is another significant target in PT-141 research. It is expressed in various tissues, including the central nervous system, and is involved in regulating energy homeostasis and other complex physiological responses. As a research tool, PT-141 enables scientists to dissect the molecular mechanisms governing MC4R-mediated pathways. This can enhance the understanding of receptor dynamics and contribute to the broader knowledge base surrounding GPCR-related research.
The synthesis of PT-141 involves complex peptide chemistry techniques, ensuring high purity and specificity for research applications. This process typically utilizes solid-phase peptide synthesis (SPPS), a method renowned for its efficiency in constructing peptides with precise sequences. The cyclic structure of PT-141 is achieved through specific cyclization strategies, which are critical for maintaining the peptide’s conformational stability and receptor-binding properties.
Once synthesized, PT-141 undergoes rigorous purification processes, often employing high-performance liquid chromatography (HPLC) to achieve the desired purity levels. This ensures that the peptide is free from contaminants that could interfere with laboratory experiments. The purity and integrity of PT-141 are essential for reproducibility and reliability in research settings, underscoring the importance of meticulous synthesis and purification protocols.
Proper handling and storage of PT-141 are vital to preserve its stability and functionality for research purposes. As with many peptides, PT-141 is sensitive to environmental conditions, necessitating specific storage practices to maintain its structural integrity. Researchers are advised to store PT-141 at low temperatures, typically -20°C or lower, to prevent degradation and preserve its efficacy for experimental use.
In addition to temperature considerations, PT-141 should be handled under conditions that minimize exposure to moisture and light, both of which can adversely affect peptide stability. Laboratory documentation practices, such as maintaining detailed records of storage conditions and usage, are crucial for ensuring the consistency and reliability of research outcomes.
PT-141 stands as a prominent figure in peptide research, offering invaluable insights into melanocortin receptor biology and the complex interplay of GPCR-mediated pathways. Its synthesis, receptor interactions, and laboratory handling considerations make it a critical tool for researchers aiming to advance the understanding of peptide-receptor dynamics. As a research-use-only chemical, PT-141 should be handled with precision and care, ensuring that its potential is fully realized within the scientific community.
Researchers interested in further exploring PT-141 and related peptides are encouraged to browse the Apex Bio Industries research catalog, which offers a comprehensive selection of high-quality research peptides designed to support cutting-edge scientific investigations.
Related in the Apex shop: PT-141 research peptide — supplied strictly for laboratory research use.
Selank peptide research starts with an unusual origin story. Most research peptides begin as fragments of a hormone or growth
Retatrutide Peptide Research: The Triple Agonist, TRIUMPH Trials and FDA Status Retatrutide peptide research is where incretin science stopped adding
Sermorelin Peptide Research: GHRH(1-29), GH Pulses and FDA History Sermorelin peptide research occupies an unusual place in the peptide literature:
